This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Are Medical Stocks Lagging Amgen (AMGN) This Year?
by Zacks Equity Research
Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
Amgen (AMGN) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?
by Kinjel Shah
JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.
Amgen (AMGN) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $295.18, marking a -1.73% move from the previous day.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
by Kinjel Shah
TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
by Kinjel Shah
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $297, moving +1.38% from the previous trading session.
Amgen (AMGN) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
The latest trading day saw Amgen (AMGN) settling at $296.85, representing a +2.18% change from its previous close.
Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?
by Kinjel Shah
JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine sales.
Trading Rotation Kicks Off 2nd Half of 2025
by Mark Vickery
Tech stocks lagged after a very strong first half of the year, while healthcare led the way.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
by Zacks Equity Research
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
by Ahan Chakraborty
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
by Kinjel Shah
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
Here's Why Amgen (AMGN) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735
by Zacks Equity Research
Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.
Amgen (AMGN) Stock Moves 1.03%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Amgen (AMGN) closed at $280.35, indicating a +1.03% shift from the previous trading day.
Here's Why Amgen (AMGN) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care
by Debanjana Dey
HIMS expands its weight loss platform with a bundled Wegovy program and tech-driven obesity care solutions.
Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $272.44, marking a -5.84% move from the previous day.
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
by Kinjel Shah
JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.